Stay Updated on the Upcoming ReSPECT-PBC Clinical Trial

Fill out the form below to connect with our team and learn more about potential eligibility once enrollment opens.

Trial Information

Pediatric brain cancer is relatively rare. However, cancer is the leading cause of death by disease among children in the U.S.  Brain and spinal cord tumors are the 2nd most common cancers in children, accounting for ~26% of childhood cancers.

Plus Therapeutics is developing the REYOBIQ™ (rhenium Re186 obisbemeda) radiotherapeutic for the treatment of rare, frequently fast-growing pediatric brain and spinal cord tumors with a poor prognosis – ependymoma and high-grade glioma (HGG) in a study known as the ReSPECT-PBC (Pediatric Brain Cancer) U.S. Phase 1 Clinical Trial. If you are interested in learning more, please fill out the form above. 

NATIONAL TRIAL REFERENCE NUMBER

NCT0706162

 

Single Group

  • All patients who enroll in the trial will receive medication while on the study.
  • All patients will receive a single dose of REYOBIQ™ (rhenium Re186 obisbemeda).

Phase 1

  • A Phase 1 study is the first step in testing a new treatment in humans. A phase I clinical trial tests the safety, side effects, best dose, and timing of a new treatment. It may also test how the treatment affects the body. The dose is usually increased a little at a time in order to find the highest dose that does not cause harmful side effects. Phase I clinical trials usually include only a small number of patients who have not been helped by other treatments.

Progress

  • Anticipated Study Start: September 2025
  • Estimated Phase 1 Completion: TBD (the date that the last participant in a clinical study is examined or receives an intervention and that data for the primary outcome measure is collected)
  • Estimated Study Completion:  TBD (the date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events, that is, the last participant's last visit). 

Principal Investigators

There is a physician who is responsible for the scientific and technical direction of the clinical trial at each location.

andrew brenner

Ashley Plant, M.D.

Lurie Children’s Hospital of Chicago
Chicago, Illinois

SPECIALTIES:  CANCER & BLOOD DISORDERS

Dr. Plant is currently an attending physician in neuro-oncology at Ann and Robert H. Lurie Children’s Hospital of Chicago and Assistant Professor at Northwestern University Feinberg School of Medicine with a research focus on translational research and early clinical trial development for pediatric brain tumors. Currently, brain tumors are the second most common cancer diagnosis in children and the leading cause of cancer-related death in all pediatric age groups. Many children diagnosed with malignant brain tumors face a dismal prognosis at diagnosis with minimal effective treatments available. Early clinical trial development and translational research is crucial to the improvement of outcomes in pediatric neuro-oncology. Dr. Plant spent her fellowship research years in the laboratories of Glenn Dranoff, MD PhD and Jerome Ritz, MD at Dana Farber Cancer Institute focusing on immunophenotyping of pediatric brain tumors and biologic correlates of immunotherapy clinical trials. Dr. Plant has completed extra training in translational research including the Program for Clinical Effectiveness at the Harvard School of Public Health and the Markers in Cancer Course in Bethesda, MD May 2016. Dr. Plant was awarded a K12 NCI grant for translational research in nervous system tumors and was the recipient of the Stahl Family Foundation grant for early phase clinical trials in immunotherapy for pediatric neuro-oncology. She is also the first inaugural 2020 A.M. Khokhar Research Scholar award recipient and the first inaugural 2020 Will Irwin Memorial Fund Researcher. Dr. Plant is currently conducting an investigator-initiated phase 1/2 clinical trial using combination immunotherapy for diffuse intrinsic pontine glioma, a universally fatal disease. The trial combines a novel neo-antigen heat shock protein vaccine known as rHSC-DIPGVax in combination with anti-PD1 and anti-CTLA4 checkpoint blockade. The focus of Dr. Plant’s career is developing and running early phase clinical trials based on translational research in the area of pediatric neuro-oncology with a specific interest in immunotherapy.

Trial Locations

Please visit this website regularly for updates as new locations are added.

Lurie Children’s Hospital

Chicago

What Can You Do Next?

Participating in a clinical trial is an important decision. If you believe this clinical trial might be a good fit and are interested in participating, please take the next step to see if you are eligible.

Discuss With Your Physician

Anyone participating in a clinical trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll.  If you are interested in participating in a clinical trial, please talk to your physician first.

Print Friendly, PDF & Email

Print, save, or email this page to your physician to discuss at your next visit

 

Contact Us

Stay Updated on the Upcoming ReSPECT-PBC Clinical Trial

Fill out the form below to connect with our team and learn more about potential eligibility once enrollment opens.

News

June 25, 2025
Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQ™ for the Treatment of Childhood Brain Cancer

March 20, 2025

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

March 7, 2025
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

December 3, 2024

April 9, 2024
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team

November 29, 2023

Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe

  • Presentation titled “Re-186 Radiolabelled NanoLiposomes for Rare Brain and Spinal Cord Tumors”

June 8, 2023

Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting

  • Plus Therapeutics announced it will exhibit at both the Society for NeuroOncology’s (SNO) Pediatric Conference, taking place June 22-24, 2023 in Washington, D.C., and the Society of Nuclear Medicine & Molecular Imaging’s (SNMMI) Annual Meeting, taking place June 24-27, 2023 in Chicago, Illinois.

August 21, 2021

Plus Therapeutics Announces Presentation of Data from the ReSPECT™-GBM Trial and Plans for Treating Pediatric Brain Cancer

June 10, 2021

Plus Therapeutics Presents at the Sixth Biennial Pediatric Neuro-Oncology Research Conference

Publications

Resources

Updates

Highlighting Leptomeningeal Metastases at SNO/ASCO 2025

Last week, the leadership teams of Plus Therapeutics and CNSide Diagnostics came together onsite at the SNO/ASCO 2025 CNS Metastases Conference to advance the dialogue on leptomeningeal metastases (LM). LM Symposium The jointly sponsored LM presentation and panel...

read more
Respecttrials
Copyright © 2025 Plus Therapeutics, Inc. All rights reserved. ReSPECT is a trademark of Plus Therapeutics, Inc. This website is intended for a U.S. audience only.